Epithelial Ovarian Carcinoma Clinical Trial
Official title:
A Phase II, Open-Label, Non-Randomized, Pilot Study of Paclitaxel, Carboplatin and Oral Metformin for Patients Newly Diagnosed With Stage II-IV Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Initially, the prospect of metformin as a neoplastic treatment was considered for malignancies of the prostate, colon and pancreas. However, only select clinical studies involving the use of metformin in the treatment of ovarian cancer have documented improved survival rates. Since no first line regimen has demonstrated compelling superiority in the management of advanced stage ovarian carcinoma, the combination of paclitaxel, carboplatin, and metformin is of particular interest given the triplet's prospect for achieving increased synergy without compromising patient tolerability.
A phase II, open-label, non-randomized, pilot study assessing the safety, toxicity, and progression free survival of advanced stage ovarian carcinoma patients who underwent treatment with paclitaxel, carboplatin and metformin. An estimated 30 patients will be required for this study. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Recruiting |
NCT00349505 -
Intraperitoneal Hyperthermic Chemotherapy in Epithelial Ovarian Carcinoma
|
Phase 2 | |
Recruiting |
NCT05470920 -
Genetic Testing Decision Aid
|
N/A | |
Recruiting |
NCT02611024 -
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
|
Phase 1/Phase 2 | |
Withdrawn |
NCT01138137 -
N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer
|
Phase 1 | |
Terminated |
NCT02107378 -
Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma
|
Phase 2 | |
Recruiting |
NCT02344095 -
A Trial of Weekly Paclitaxel With Oncothermia and Weekly cisPlatin With Oncothermia in Patients With Recurrent or Persistent Ovarian Cancer
|
Phase 1 | |
Recruiting |
NCT05086692 -
A Beta-only IL-2 ImmunoTherapY Study
|
Phase 1/Phase 2 | |
Recruiting |
NCT04834544 -
A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care
|
Phase 2 |